Eli Lilly is considering testing its blockbuster weight-loss drugs in people who are not overweight but are at risk of weight ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

Here, Hancock cites fund holding Eli Lilly and its patents on GLP-1 weight loss drugs Mounjaro and Zepbound. Hancock expects ...

But Lilly isn't alone in the market, and in the coming years, this space could become more crowded. Today, Lilly competes ...

Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in ...

The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...

Eli Lilly explores expanding its weight-loss drugs, Mounjaro and Zepbound, to individuals with a BMI below 27 to prevent ...

The company is set to become the first $1tn drugmaker, but investors see warning signs it has reached ‘peak enthusiasm’ ...

In Q2, it brought in $11.3 billion in sales, 36% higher than a year prior, and it cranked up its annual revenue guidance for ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target ...

In a groundbreaking move, Eli Lilly LLY is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight.

The group of $1 trillion market cap stocks is tiny, and pharmaceutical giant Eli Lilly (NYSE: LLY) isn't a member yet, though ...